Partin AW - Search Results

1

SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression.

Malik G, Rojahn E, Ward MD, Gretzer MB, Partin AW, Semmes OJ, Veltri RW. Malik G, et al. Among authors: partin aw. Prostate. 2007 Oct 1;67(14):1565-75. doi: 10.1002/pros.20646. Prostate. 2007. PMID: 17705230

2

Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.

Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS, Patton KP, Criley SR, Coffey DS. Veltri RW, et al. Among authors: partin aw. J Cell Biochem Suppl. 1994;19:249-58. J Cell Biochem Suppl. 1994. PMID: 7529856 Clinical Trial.

3

Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease.

Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Carmichael MJ, et al. Among authors: partin aw. J Urol. 1995 Mar;153(3 Pt 2):1015-9. J Urol. 1995. PMID: 7853549 Free article. Clinical Trial.

4

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy.

Weinstein MH, Partin AW, Veltri RW, Epstein JI. Weinstein MH, et al. Among authors: partin aw. Hum Pathol. 1996 Jul;27(7):683-7. doi: 10.1016/s0046-8177(96)90398-6. Hum Pathol. 1996. PMID: 8698312 Free article.

5

Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.

Veltri RW, Miller MC, Partin AW, Coffey DS, Epstein JI. Veltri RW, et al. Among authors: partin aw. Urology. 1996 Nov;48(5):685-91. doi: 10.1016/S0090-4295(96)00370-6. Urology. 1996. PMID: 8911509

6

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate.

Silberman MA, Partin AW, Veltri RW, Epstein JI. Silberman MA, et al. Among authors: partin aw. Cancer. 1997 Feb 15;79(4):772-9. doi: 10.1002/(sici)1097-0142(19970215)79:4<772::aid-cncr14>3.0.co;2-x. Cancer. 1997. PMID: 9024715

7

Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23.

Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW. Subong EN, et al. Among authors: partin aw. Prostate. 1999 Jun 1;39(4):298-304. doi: 10.1002/(sici)1097-0045(19990601)39:4<298::aid-pros11>3.0.co;2-m. Prostate. 1999. PMID: 10344220

8

Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.

Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW, Partin AW. Potter SR, et al. Among authors: partin aw. Urology. 1999 Nov;54(5):791-5. doi: 10.1016/s0090-4295(99)00328-3. Urology. 1999. PMID: 10565735 Free article.

9

Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.

Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Miller MC, et al. Among authors: partin aw. Urology. 2001 Jun;57(6):1105-11. doi: 10.1016/s0090-4295(01)00953-0. Urology. 2001. PMID: 11377319

10

Quantitative nuclear grade (QNG): a new image analysis-based biomarker of clinically relevant nuclear structure alterations.

Veltri RW, Partin AW, Miller MC. Veltri RW, et al. Among authors: partin aw. J Cell Biochem Suppl. 2000;Suppl 35:151-7. doi: 10.1002/1097-4644(2000)79:35+<151::aid-jcb1139>3.0.co;2-7. J Cell Biochem Suppl. 2000. PMID: 11389545 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

611 results

Search Page